[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Guillem V, Poveda A: Germ cell tumours of the ovary. Clin Transl Oncol; 2007 Apr;9(4):237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumours of the ovary.
  • Germinal cell tumours represent only 2-5% of all cancers of the ovary.
  • The surgical treatment demands the application of the same principles seen in cytoreduction surgery of epithelial cancers of the ovary (maximum possible cytoreduction), though in many cases hysterectomy and double adnexectomy may be obviated.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Ovarian Neoplasms
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Child. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Chorionic Gonadotropin, beta Subunit, Human. Dysgerminoma / diagnosis. Dysgerminoma / drug therapy. Dysgerminoma / pathology. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Female. Humans. Neoplasm Staging. Ovary / pathology. Prognosis. Randomized Controlled Trials as Topic. Teratoma / diagnosis. Teratoma / drug therapy. Teratoma / pathology. World Health Organization. alpha-Fetoproteins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462976.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 49
  •  go-up   go-down


2. Taguchi A, Takeshita S, Machida R, Hori Y, Aida K, Furuya U, Ohe E, Murase T, Shinozuka N, Ayabe T, Mori H: [Anaphylaxia induced by etoposide--a case report]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Under the clinical diagnosis of choriocarcinoma, she underwent total hysterectomy with right salpingooophorectomy.
  • The ovarian choriocarcinoma was confirmed by pathologic examination.
  • This episode was thought to have been induced by etoposide, but etoposide was a key agent for choriocarcinoma.
  • The etoposide concentration was diluted to 50%, and the drug administration rate reduced by half.
  • The few reports on anaphylaxic reactions to chemotherapeutic agents induced by side effects must be taken into account when we use these drugs.
  • [MeSH-major] Anaphylaxis / chemically induced. Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects
  • [MeSH-minor] Adult. Choriocarcinoma / drug therapy. Female. Humans. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938279.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


3. Jondle DM, Shahin MS, Sorosky J, Benda JA: Ovarian mixed germ cell tumor with predominance of polyembryoma: a case report with literature review. Int J Gynecol Pathol; 2002 Jan;21(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mixed germ cell tumor with predominance of polyembryoma: a case report with literature review.
  • An ovarian mixed germ cell tumor in a 34-year-old woman contained a predominant component of polyembryoma as well as foci of choriocarcinoma, yolk sac tumor, and immature teratoma.
  • [MeSH-major] Germinoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Choriocarcinoma / surgery. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Histocytochemistry. Humans. Hysterectomy. Ovariectomy. Pregnancy. Teratoma / drug therapy. Teratoma / pathology. Teratoma / surgery


Advertisement
4. Kohorn EI, Kacinski BM, Stanley ER: Serum levels of macrophage colony-stimulating factor in trophoblastic disease. Gynecol Oncol; 2001 Mar;80(3):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor. hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule.
  • [MeSH-minor] Adolescent. Adult. Aged. Chorionic Gonadotropin / blood. Female. Humans. Hydatidiform Mole / blood. Hydatidiform Mole / drug therapy. Male. Middle Aged. Predictive Value of Tests. Pregnancy. Radioimmunoassay. Risk Factors

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11263936.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA26504; United States / NCI NIH HHS / CA / CA32551; United States / PHS HHS / / P30-13330
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


5. Jiao LZ, Xiang Y, Feng FZ, Wan XR, Zhao J, Cui QC, Yang XY: Clinical analysis of 21 cases of nongestational ovarian choriocarcinoma. Int J Gynecol Cancer; 2010 Feb;20(2):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of 21 cases of nongestational ovarian choriocarcinoma.
  • INTRODUCTION: The objective of the study was to investigate the clinical characters, diagnosis, treatment, and prognosis of nongestational ovarian choriocarcinoma.
  • METHODS: A retrospective analysis was done on 21 patients with nongestational ovarian choriocarcinoma treated in Peking Union Medical College Hospital from January 1985 to October 2008.
  • All patients' conditions were diagnosed by histopathologic examination; in 3 of them, the diagnosis was confirmed by DNA polymorphism analysis at 12 short tandem repeat loci.
  • RESULTS: Correct diagnosis was achieved in only 3 patients before initial treatment.
  • All patients received standard multiple-drug combined chemotherapy and underwent an operation.
  • CONCLUSIONS: The early diagnosis of nongestational ovarian choriocarcinoma is expected to be improved.
  • DNA polymorphism analysis is a useful tool in determining the origin of ovarian choriocarcinoma.
  • The prognosis is optimistic if managed with standard multiple-drug chemotherapy combined with surgical treatment.
  • [MeSH-major] Choriocarcinoma, Non-gestational / diagnosis. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134273.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Koo HL, Choi J, Kim KR, Kim JH: Pure non-gestational choriocarcinoma of the ovary diagnosed by DNA polymorphism analysis. Pathol Int; 2006 Oct;56(10):613-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure non-gestational choriocarcinoma of the ovary diagnosed by DNA polymorphism analysis.
  • Pure primary ovarian choriocarcinoma is a rare condition that can be of gestational or non-gestational origin.
  • Non-gestational choriocarcinoma has been found to be resistant to single-agent chemotherapy and has a worse prognosis than gestational choriocarcinoma, but it is difficult to distinguish the two types by routine histological examination.
  • Herein is reported a case of primary pure non-gestational choriocarcinoma of the ovary in a 33-year-old nulligravid woman, as confirmed by DNA polymorphism analysis.
  • This case demonstrates the usefulness of DNA polymorphism analysis for the determination of the origin of extrauterine choriocarcinoma.
  • [MeSH-major] Choriocarcinoma, Non-gestational / diagnosis. DNA, Neoplasm / genetics. Ovarian Neoplasms / diagnosis. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984618.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


7. Kanazawa K, Suzuki T, Sakumoto K: Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Am J Clin Oncol; 2000 Jun;23(3):244-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission.
  • To describe our experience with malignant ovarian germ cell tumors with special reference to reproductive performance after remission, medical records of 31 patients were reviewed.
  • The mean age at diagnosis was 18.6 years.
  • Tumor by stage was I in 16 cases, II in 5, III in 5, IV in 3, and recurrence in 2.
  • Histology was dysgerminoma in 7 cases, yolk sac tumor in 10, immature teratoma in 7, choriocarcinoma in 1, and mixed-type tumor in 6.
  • Of the remaining 12 nonpregnant cases, 3 married, 9 have had regular menses, and 3 have had menstrual problems.
  • Thus, management of the disease with fertility preservation is safe and the majority of patients can attain or retain normal ovarian function and reproductive potential.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dysgerminoma / drug therapy. Endodermal Sinus Tumor / drug therapy. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy. Reproduction / drug effects
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Fertility / drug effects. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Menstruation / drug effects. Methotrexate / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857886.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate; BEP protocol; EMACO protocol; MAC combination; VAC protocol
  •  go-up   go-down






Advertisement